Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate

Cadrenal Therapeutics (NASDAQ: CVKD) reported a Q4 loss of $(1.41) per share, missing the analyst consensus estimate of $(1.18) by 19.49%. This represents a 49.64% improvement compared to losses of $(2.80) per share in the same quarter last year.